Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03866798 · ClinicalTrials.gov registry record · Phase 4
Study to Evaluate the Efficacy and Safety of PANZYGA in Pediatric Patients With Chronic Immune Thrombocytopenia (ITP)
A Phase 4 study, sponsored by Octapharma.
- Terminated
- Registry status
- Phase 4
- Development phase
- 6
- Enrollment target
NCT03866798 is a Phase 4 study that was terminated before completion, run by Octapharma. The registered enrollment target is 6 participants.
The verdict
NCT03866798, a Phase 4 study, was terminated before completion, sponsored by Octapharma.
- TERMINATED
- Registry status
- Phase 4
- Development phase
- 6 participants
- Enrollment target
Study Summary
This is a prospective, open-label, single-arm, multicenter, Phase 4 study evaluating the efficacy and safety of PANZYGA in pediatric patients with chronic ITP.
Interventions
- BIOLOGICAL Panzyga
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 6 participants |
| Start Date | 2020-01-21 |
| Est. Completion | 2024-05-17 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03866798
The ClinicalTrials.gov registry entry for NCT03866798 describes a study currently listed as terminated, categorized as Phase 4. The registered enrollment target is 6 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Octapharma, which has 43 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Panzyga is the first listed.
NCT03866798 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03866798 about?
NCT03866798 is a clinical study titled "Study to Evaluate the Efficacy and Safety of PANZYGA in Pediatric Patients With Chronic Immune Thrombocytopenia (ITP)". This is a prospective, open-label, single-arm, multicenter, Phase 4 study evaluating the efficacy and safety of PANZYGA in pediatric patients with chronic ITP.
What is the current status of trial NCT03866798?
This trial is currently terminated. It is a Phase 4 study. The enrollment target is 6 participants. The study started on 2020-01-21. Estimated completion is 2024-05-17.
What interventions are being tested in trial NCT03866798?
The interventions under investigation include: Panzyga (BIOLOGICAL).
Who is sponsoring clinical trial NCT03866798?
This trial is sponsored by Octapharma, which has 43 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.